Table 1 Clinical characteristics.
Test cohort | Validation cohort | ||||||
|---|---|---|---|---|---|---|---|
High EF | Low EF | P value | |||||
(n = 16) | (n = 16) | (high vs low EF) | (n = 115) | ||||
4-months EF, % (median-range) | 63 | 45-73 | 35 | 20-40 | 0.0003 | 40 | 15-86 |
Age, y (median-range) | 56 | 43-84 | 68 | 38-83 | 0.57 | 56 | 32-90 |
Sex (male, n, %) | 13 | 81% | 13 | 81% | 1 | 98 | 85% |
Body Mass Index (median-range) | 28 | 23-35 | 26 | 20-38 | 0.25 | 27 | 19-43 |
Serum markers (median-range) | |||||||
Troponin T (ng/mL) | 0.78 | 0.06-10.69 | 11.64 | 1.46-26.1 | 0.007 | 4.76 | 0.03-26.1 |
CPK (units/L) | 762 | 603-3798 | 4860 | 1015-9383 | < 0.001 | 1978 | 602-9383 |
Cardiovascular history, n (%) | |||||||
Prior MI | 2 | 13% | 3 | 19% | 0.64 | 7 | 6% |
CABG | 0 | 0% | 1 | 6% | 0.33 | 3 | 3% |
PTCA | 1 | 6% | 2 | 13% | 0.56 | 11 | 10% |
Diabetes | 4 | 25% | 6 | 38% | 0.46 | 22 | 19% |
Hypertension | 6 | 38% | 7 | 44% | 0.73 | 47 | 41% |
Hypercholesterolemia | 7 | 44% | 9 | 56% | 0.50 | 45 | 39% |
Tobacco | 4 | 25% | 5 | 31% | 0.71 | 53 | 46% |
Medications, n (%) | |||||||
Beta-blockers | 16 | 100% | 14 | 88% | 0.16 | 98 | 85% |
Calcium antagonists | 3 | 19% | 0 | 0% | 0.08 | 0 | 0% |
Nitrates | 6 | 38% | 6 | 38% | 1 | 31 | 27% |
ACE inhibitors | 10 | 63% | 10 | 63% | 1 | 51 | 44% |
Statins | 14 | 88% | 14 | 88% | 1 | 89 | 77% |
Angiotensin receptor inhibitors | 2 | 13% | 0 | 0% | 0.16 | 1 | 1% |